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Interferon  (IF) 1 is  known  for  its  effect  on  virus  cell  interactions  (1).  The  first 
indication that it could influence cellular cytotoxicity was provided by Svet-Moldav- 
sky and Chernyakovskaya in  1967 (2), when they observed that lymphocyte-mediated 
killing was enhanced in the presence of IF. Their system comprised mouse lymphocytes 
and the L  cell line.  This finding was not followed up until  1972 when Lindahl et al. 
(3) reported that IF enhanced the specific cytotoxicity of allosensitized murine T  cells. 
Recent experiments  established  that  exposure of lymphocytes to IF in vitro elevates 
their  natural  killer  (NK)  activity  (4-6).  In  addition,  treatment  of the  lymphocyte 
donors with IF or IF inducers also leads to increased in vitro cytotoxic potential  (7-9). 
The cytotoxic system is influenced  in the opposite direction  if the targets are treated 
with IF inasmuch as their susceptibility for killing is decreased  (10). 
IF is used in tumor therapy because of its antitumor  (11), antiviral,  and immuno- 
potentiating  effects.  Beneficial  effects  have been  reported  for Hodgkin's lymphoma 
(12), myelomatosis (13), malignant  lymphoma, (14)  and leukemia  (15). 
In  the  majority  of studies  dealing  with  NK  and  the  IF-activated  killing  (IAK), 
established  cell lines were used as targets.  In experimental  systems, freshly harvested 
cells  usually  had  lower  NK  sensitivity  than  cultured  lines  (16,  17).  Also,  in  man, 
tumor  cells  isolated  from  biopsies  were  generally  NK  resistent,  i.e.,  they  were  not 
killed  by  allogeneic  lymphoeytes  derived  from  healthy  donors  (18).  On  the  other 
hand, a tumor-specific reactivity was indicated in 28% of 156 cases because the biopsy 
cells  were  damaged  by the  autologous  lymphocytes  (19).  We  refer  to  this  effect  as 
autologous lymphocyte-mediated cytotoxicity (ALC). 
The experiments  reported  in this  paper were initiated  with the aim to investigate 
whether IF treatment  in vitro influences the ALC. Such effects would have provided 
an  in  vitro  correlate  for  the  therapeutical  effect  of IF.  The  results  were  negative 
inasmuch as no ALC was induced. The ALC-negative cases remained  negative, and 
no elevation of the existing effects occurred. 
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An interesting phenomenon, however, was discovered in that  IF-induced cytotox- 
icity was efficient only in allogeneic combinations. Because the IAK has been shown 
to be performed by those lymphocyte subsets that are also responsible for the NK (20, 
21),  this  finding may contribute to  the understanding of the  NK mechanism. It  is 
likely that IF activates the cytotoxic potential of the lymphocyte population, and that 
those cells that  carry the receptors  for the histocompatibility antigens expressed on 
the particular target can manifest the cytotoxic function. 
Materials and Methods 
Patients.  43 patients with solid tumors of various histologic types were studied (Table I). 
Except  for  eight  patients  (1019,  1020, 1023, 1024, 1027, 1032, 1034, and  1035) who  had 
osteosarcomas and were  receiving IF (3  million U/d)  and seven patients (1127,  1120, 1113, 
0788, 0508, 0509, 0510) who were operated earlier for their primary tumors, the patients were 
not treated before the tumor and blood sampling. 
Tumor Cells.  These cells were separated from biopsy specimens according to our procedure 
described elsewhere  (22), by the stepwise application of velocity and density sedimentations on 
Ficoll-Isopaque (FI)  (Pharmacia Fine Chemicals, Inc., Upsala, Sweden) and/or human serum 
albumin gradients, treatment with collagenase and DNase, and adherence to plastic surface. 
The isolated tumor cells were incubated overnight in culture conditions before the cytotoxic 
test to allow regeneration of putative antigens assumed to be affected during the procedures of 
cell separation. Experiments were  performed only with cell suspensions that had at least  80% 
cell viability, as assessed by trypan blue exclusion, and had <5% obvious contamination with 
nonmalignant  cells. 
Storage of Tumor Cells.  Samples of tumor cells (2-5 X 106) were stored in liquid nitrogen for 
use as  targets in repeated  tests.  The cells were  suspended in 0.5  ml of RPMI-1640 medium 
(Flow Laboratories, Ltd., Irvine, Ayrshire, Scotland) that contained 40% normal human serum 
(NHS),  after  which  0.5  ml  of 20%  dimethyl sulfoxide in  RPMI-1640  medium was  added 
dropwise.  Ampules were  frozen at  l°C/min. After thawing, cells were  diluted to  10 ml with 
RPMI-1640 medium plus 20%  NHS, centrifuged, and resuspended in RPMI-1640 medium 
plus  10% NHS. When necessary,  dead cells were  removed by centrifugation on FI gradients. 
Cell  Lines.  The erythroid  line K-562 was  derived from  a  patient with  chronic myeloid 
leukemia in blast crisis  (23). The T  cell  line Moh-4 was obtained from a patient with acute 
lymphoid leukemia (24). They were maintained in suspension culture in RPMI-1640 medium 
supplemented with 10% fetal calf serum. 
Lymphocytes.  Lymphocytes from  43  patients and 49 healthy donors were separated  from 
heparinized blood on FI, followed  by incubation in Falcon plastic culture flasks  (type 3024, 
Falcon Labware, Div. of Becton, Dickinson & Co., Oxnard, Calif.) for 30 min at 37°C and by 
passage  through  a  nylon  fiber  column  (25). The  nylon  fiber  column-passed  populations 
contained 91  +  6%  sheep erythrocyte-rosetting cells.  Contamination with cells of obviously 
nonlymphocyte morphology represented <1%. 
IF Preparations.  The partially purified Sendal virus-induced human leukocyte IF prepara- 
tions were received from Dr. Kari Cantell, Central Public Health Laboratory, Helsinki, Finland. 
They were produced and purified as previously described (26). The antiviral activities of the 
preparations were determined by assaying inhibition  of plaques induced by vesicular stomatitis 
virus  in  human  amnion  (U)  cells  (27) and  expressed  in  international reference  units  by 
comparison with the international reference preparation 69/19. The antiviral activities of the 
preparations were ~6 x  106 U/ml, with an ~ 106 U/mg of protein sp act. 
IF Treatment  of the Lymphocytes.  Aliquots of lymphocytes (3-10 X  106) were incubated with 
or without  1,000 U/ml IF for  1 3 h at 37°C in culture medium. The cells were then washed 
and used as effectors in the cytotoxicity tests. IF treatment of the lymphocytes had no effect on 
cell viability as assessed after crystal violet staining. The cytotoxicity of these lymphocytes will 
be referred to as IAK. 
Medium.  RPMI-1640 medium with L-glutamine (200 mM solution, 1~7~ by vol), benzylpen- 
icillin (100 IU/ml), streptomycin sulfate (100/Lg/ml), Hepes buffer (0.1 mM/ml), and heat- F.  T.  V,~NKY,  S.  A.  ARGOV,  S.  A.  EINttORN,  AND  E.  KLEIN  1153 
TABLE  I 
List of Patients 
Patient 
D i fferen  - 
num-  Sex  Age  Diagnosis  Clinical stage  tiation* 
her 
1019  M  20  Osteosarcoma  Localized  L 
1020  M  20  Osteosarcoma  Localized  L 
1023  M  15  Osteosareoma  Lung metastasis  L 
1024  F  14  Osteosarcoma  Localized  L 
1027  M  25  Osteosarcoma  Localized  L 
1032  M  15  Osteosarcoma  Localized  L 
1034  M  17  Osteosarcoma  Localized  L 
1035  M  11  Osteosarcoma  Lung metastasis  L 
1025  M  51  Malignant chordoma  Local recurrence  D 
1028  M  74  Malignant mesenchymal tumor  Lung metastasis  U 
1031  M  70  Malignant mesenchymal tumor  Localized  U 
1115  F  77  Malignant mesenchymal tumor  Localized  U 
1131  M  75  Malignant histiocytic tumor  Lymph node metastasis  L 
1033  M  43  Fibrosarcoma of the tibia  Localized  L 
1126  M  59  Fibrosarcoma  Localized  L 
1130  F  71  Myxoid fibrosarcoma  Localized  L 
1127  M  77  Liposarcoma  Local recurrence  L 
0111  M  43  Liposarcoma  Localized  L 
1120  M  52  Myxoid liposarcoma  Local recurrence  D 
1121  F  60  Myxoid liposarcoma  Localized  D 
1117  F  76  Synovial sarcoma  Localized  L 
1 l 13  F  60  Melanoma  Lung metastasis  D 
0788  F  46  Melanoma  Brain metastasis  D 
2256  F  52  Thymoma  Localized  D 
2258  M  59  Thymoma  Localized  D 
2259  F  58  Thymoma  Localized  D 
0500  M  55  Hypernephroma  Localized  D 
0508  M  54  Hypernephroma  Lung metastasis  L 
0509  M  66  Hypernephroma  Lung metastasis  L 
0510  F  70  Hypernephroma  Brain metastasis  L 
2217  M  69  Adenocarcinoma of the lung  Lymph node metastasis  D 
2224  M  62  Adenocarcinoma of the lung  Localized  L 
2229  F  51  Adenocarcinoma of the lung  Localized  D 
0470  M  80  Adenocarcinoma of the lung  Localized  D 
2225  M  63  Squamous cell carcinoma of the lung  Localized  L 
2234  F  59  Squamous cell carcinoma of the lung  Localized  D 
2244  M  51  Squamous cell carcinoma of the lung  Localized  L 
2255  M  50  Squamous cell carcinoma of the lung  Localized  L 
0012  M  72  Squamous cell carcinoma of the lung  Inoperable  L 
0013  M  61  Squamous cell carcinoma of the lung  Inoperable  D 
2219  M  67  Oat cell carcinoma of the lung  Lymph node metastasis  U 
0784  F  51  Astrocytoma grade III 
0787  F  25  Astrocytoma grade II 
* L, low differentiation; U, undifferentiated;  D, differentiated. 
inactivated  serum  (from  healthy  male  donors)  added  in  10%  concentration  was  used  in  all 
experiments. NI-IS were not preselected,  but cloudy sera were excluded. 
Cytotoxicity Assay.  A  modification of the method described by Vose et al.  (28) has been used. 
Target  cells  (106)  were  labeled  in 0.5  ml  medium  by the addition  of 100/~Ci  ~ICr  (as sodium 1 154  CELL-MEDIATED  KILLING  OF  TUMOR  BIOPSY  CELLS 
TABLE  II 
Effect of IF on the Cytotoxicity of Lymphocytes Against Autologous and Allogeneic Tumor Biopsy Cells and 
Against K-562 
Lymphocytes 
Donor  Incu- 
bated 
Number  Diagnosis  with IF* 
Targets 
Tumor biopsy cell number 
1115  2219 
K-562 
1115  Malignant mesenchymal tumor  -  8 (27)~  5 (37)  22 (25) 
+  6  44§  31 
0111  Liposarcoma  -  22  4  19 
+  761]  27¶  41§ 
Healthy  -  11  4  25 
+  33§  22¶  38§ 
* The lymphocytes were incubated with 1,000 U/ml IF for 1 h and washed before the test. 
:~ The values represent  the percent  specific  51Cr release  and  those  in  parentheses indicate the  percent 
spontaneous SlCr release. 
§ P <  0.01 between the values obtained with lymphocytes with and without IF treatment. 
]] P <  0.001 between the values obtained with lymphocytes with and without IF treatment. 
¶ P <  0.05 between the values obtained with lymphocytes with and without IF treatment. 
chromate;  100-350 ~Ci//~g sp act; The Radiochemical Centre, Amersham, Buckinghamshire, 
England).  After incubation for 2  h  at  37°C  the cells were washed  twice.  They  were  further 
incubated for  1 h, washed twice, and resuspended  in culture medium. Target  cells  (5  ×  10:~/ 
well)  were  dispensed  into wells of round-bottom  microplates  (96 wells/plate;  Titertek,  Flow 
Laboratories, Ltd.). Lymphocytes were then added to give an effector:target ratio of 50:1. The 
final vol  in each well was 0.2  ml. The  plates were centrifuged  for  10 s  at  800 g.  After a  4-h 
incubation  at  37°C,  the  supernates  and  the  pellets  were  collected  separately  (by  means  of 
Titertek) and the radioactivity in the supernate and pellet was measured in a  gamma counter. 
Spontaneous ~Cr release was measured from target cells incubated in medium; maximum ~lCr 
release was obtained by lysis of the cells with detergent (Triton X-100, Sigma Chemical Co., St. 
Louis, Mo.). 
Test evaluation.  The percentage of ~lCr release was calculated from the following formula: 
(counts in supernate/counts in supernate and pellet)  ×  100. The percent specific 51Cr  release 
was then determined by the following formula:  (percent release in test -  percent spontaneous 
release)/(percent maximum release -  percent spontaneous release)  ×  100. Tests in which the 
spontaneous release exceeded 50% were disregarded. Statistical significances were calculated on 
the triplicates by the Student's t test. A  further criteria for the positivity of ALC was that the 
level  of specific  51Cr  release  had  to  be  twice  over  the  control.  This  was  obtained  by  the 
experiments performed between lymphocytes from 47  healthy donors and tumor biopsy cells 
from  45  patients.  On  the  basis  of these  results  20%  specific  release  was  chosen  as  limit  for 
positivity. Specific 5XCr release >20% was always significant by the Mann-Whitney U  test and 
was arbitrarily chosen as limit for positivity. This may be too high, and, therefore, it is likely 
that some of the positive effects are not considered. In the present series, the cytotoxic efficiencies 
of untreated and IF-treated lymphocytes were compared;  thus, the limit for determining the 
positivity is of secondary importance.  Positivity for changes of cytotoxicity caused  by IF was 
established on  the  basis  of statistical  significance  between  counts  per  minute  values  of the 
triplicates. 
Results 
Effect  of IF on  Lymphocyte  Cytotoxicity  Against  Primary  Tumor  Biopsy  Cells.  Table  II 
presents the results of an experiment  in which  two patients  (malignant  mesenchymal 
tumor  1115  and  liposarcoma  011 1)  and  one  healthy  donor  were  involved.  After 
pretreatment  of the  lymphocytes  with  IF,  the  NK  activities  were  measured  as  the F.  T.  V,~NKY,  S.  A. ARGOV, S.  A.  EINHORN,  AND E.  KLEIN  1 155 
TABLE III 
Effect of IF on the Cytotoxicity of Lymphocytes Against Autologous and Allogeneic Tumor Biopsy Cells and 
Against Molt-4 
Lymphocytes 
Donor  Incu- 
bated 
Number  Diagnosis  with IF* 
Targets 
Tumor biopsy cell number 
0509  0508 
Moh-4 
0509  Hypernephroma  -  50 (42):1:  10 (38)  14 (24) 
0509  Hypernephroma  +  45  26§  21 
0508  Hypernephroma  -  2  0  32 
0508  Hypernephroma  +  47[[  5  40§ 
Healthy  -  43  24  89 
Healthy  +  62[[  83[[  83 
* The lymphocytes were incubated with  1,000 U/ml IF for 1 h and washed before the test. 
:~ The values represent  the percent  specific 51Cr release and  those in  parentheses  indicate the percent 
spontaneous 5~Cr release. 
§ P < 0.05 between the values obtained with lymphocytes with and without IF treatment. 
[[ P < 0.001 between the values obtained with lymphocytes with and without IF treatment. 
elevated anti-K-562 effect. Except for the effect of the 0111  lymphocytes on the  1115 
targets, the effects against primary biopsy cells were weaker than  against K-562.  IF 
treatment regularly enhanced  the killing of allogeneic targets. This was not the case 
for ALC. 
The results of an experiment with lymphocytes from two hypernephroma patients 
and one healthy blood donor are given in Table III. The NK activity of the patients, 
as measured against Molt-4, was weaker than  that of the control donor. The strong 
NK activity of the lymphocytes of the healthy donor is also reflected by the cytotoxicity 
against  the biopsies. The  lymphocytes of patient  0509  killed the  autologous tumor 
cells.  This  activity was  not  elevated  by  IF  pretreatment,  whereas  allo-killing was 
induced. The lymphocytes of patient 0508 were inactive against both the autologous 
and  the  allogeneic  tumor  cells.  IF  treatment  of  the  lymphocytes  induced  strong 
cytotoxicity against the allogeneic biopsy cells. 
Table IV shows a  test with lymphocytes and tumor cells from a  synovial sarcoma 
(1117)  and an osteosarcoma  (1020)  patient.  The standard  NK activity (anti-K-562) 
of the lymphocytes of the patients was  autgmented  by IF. Cytotoxicity against the 
biopsy cells was increased by IF only in the allogeneic combinations. 
The  summary  of ALC  experiments  with  lymphocytes from  25  tumor  patients  is 
presented in Fig.  1 a  and Table V.  ALC occurred  in  7  (28%)  cases. In an additional 
four  cases,  the  specific  SlCr  release  was  between  10  and  20%.  In  24  of  25  cases, 
incubation of the lymphocytes with IF did not significantly change the level of ALC, 
whereas in one it decreased the killing potential (of the 24 cases in which the change 
was not significant, the 51Cr-release values were higher in  10 and lower in  10 cases). 
The results of cytotoxicity against allogeneic biopsy targets with lymphocytes from 
46 healthy donors and 24 tumor patients are presented in Fig.  1 b  and c, respectively. 
The  controls were  active  in  7  of 50  (14%)  tests  (Fig.  1 b),  and,  in  5  of these  7,  IF 
increased  the  cytotoxic  efficiency.  Of  the  43  negative  tests,  IF  treatment  caused 
significant cytotoxicity in 22. The specific 51Cr release was somewhat enhanced in an 
additional 10 cases, diminished in 7, and equal to that of untreated samples in 6. The 1 156  CELL-MEDIATED KILLING OF TUMOR  BIOPSY  CELLS 
TABLE  IV 
Effect of IF on the Cytotoxicity of Lymphocytes Against Autologous and AUogeneic Tumor Biopsy Cells and 
Against K-562 
Lymphocytes  Targets 
Donor  Incu-  Tumor biopsy cell number 
bated 
Number  Diagnosis  with IF*  1117  1020 
K-562 
1117  Synovial sarcoma  -  17 (40):~  4 (44)  36 (28) 
1117  Synovial sarcoma  +  20  14  57§ 
1020  Osteosareoma  -  9  20  4 
1020  Osteosarcoma  +  3111  22  26§ 
Healthy  -  7  0  28 
Healthy  +  3011  3311  32 
* The lymphocytes were incubated with 1,000 U/ml IF for 3 h and washed before the test. 
:~ The  values  represent  the  percent  specific  ~Cr release  and  those  in  parentheses  indicate  the  percent 
spontaneous SlCr release. 
§ P <  0.01 between the values obtained with lymphocytes with and without IF treatment. 
I1 P <  0.001 between the values obtained with lymphocytes with and without IF treatment. 
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Fic.  1.  Influence of IF on the cytotoxic potential of lymphocytes exerted on primary tumor cells 
(a)  in autologous combination, (b)  by lymphocytes of healthy donors,  and  (c) by lymphocytes of 
tumor patients towards  allogeneic target cells. 
increase  (_ SE) in the mean percent specific 51Cr release with IF-treated lymphocytes 
from healthy donors was  12 ±  2.6, and  this was statistically significant  (P <  0.001). 
The results with the tumor patients were similar. They showed a  significantly lower 
proportion  of allogeneic cytotoxicity, i.e., in  2  of 37  (5%)  of the tests  (Fig.  1 c).  In  18 
of 37 tests, IF-treated lymphocytes exhibited significant cytotoxicity. The specific 51Cr 
release  was  elevated  in  an  additional  eight  cases,  diminished  in  eight,  and  equal  to F.  T.  V,~NKY,  S.  A.  ARGOV,  S.  A.  EINHORN,  AND  E.  KLEIN 
TABLE  W 
IF-induced Cytotoxicity of Blood Lymphocytes Against  Tumor Biopsy Cells 
1157 
Effector lymphocyte from 
Targets (tumor 
biopsy cells) 
Tumor patient  Healthy donor 
IF- 
Change in  Change in 
IF+  percent SlCr  IF-  IF+  percent SlCr 
release  release 
7/25 (28%)*  7/25 (28%)  -0.3 +  1.6:~  --  -- 
AllogeneicAUt°l°g°us  2/37 (5%)  18/37 (49%)  12.7 ±  2.6  7/50 (14%)  26/50 (52%)  14.9 ±  2.2 
call  signi  t cytot )xicit)  r numl ,e  er (  .~sts. 
rea~ ~r of th  cific n], 2r rek  r +  SE, as ~  suit of IF tr  ment of the 
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* Cases with statistically significant cytotoxicity per number of tests. 
:~ Mean percent increase of the specific S]Cr release +  SE, as a result of IF treatment of the effectors. 
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Influence of IF on the (A) anti-K-562 and (0) anti-Moh-4 activity oflymphocytes of tumor 
that of untreated  lymphocytes  in three. The  difference in the mean  percentage specific 
51Cr  release  (+_  SE)  between  the  IAK  and  NK  was  14.9  +  2.2,  and  this  was  also 
statistically significant  (P <  0.001). 
A  summary  of the IAK  results is given in Table  V. ALC  was similar with IF-treated 
and  untreated  lymphocytes.  The  mean  percentage  of difference was  -0.3  ---  1.6.  The 1 158  CELL-MEDIATED KILLING OF TUMOR  BIOPSY CELLS 
TABLE VI 
Elevated Susceptibility of Cultured Tumor Biopsy Cells for the Cytotoxic Effect of Autologous and Allogeneic 
Lymphocytes 
Lymphocyte donor  Incubation  Tumor donor 
number  with IF*  number 
Percent specific cytotoxicity of target cells 
Cultured:~  Kept frozen  Used fresh 
2259  -  2259  21  (22)§  8 (27)  3 (31) 
2259  +  2259  26  13  0 
Healthy donor  -  2259  36  15  NT 
Healthy donor  +  2259  68 H  43¶  NT 
0788  -  0788  22 (26)  4 (32)  0 (38) 
0788  +  0788  37**  2  2 
Healthy donor  -  0788  20  4  NT 
Healthy donor  +  0788  25  13  NT 
0510  --  0510  5 (37)  2 (29)  0 (34) 
0510  +  0510  34¶  4  3 
1131  -  0510  2  0  NT 
1131  +  0510  27 II  24¶  NT 
Healthy donor  -  0510  0  NT  5 
Healthy donor  +  0510  20 II  NT  0 
* The lymphocytes were incubated with 1,000 U/ml IF for 1 h and washed before the test. 
:~ The target cells were cultured for 5 d in RPMI-1640 medium enriched with 10% NHS. 
§ The values represent  the percent  specific  51Cr release  and  those  in  parentheses  indicate the percent 
spontaneous 5~Cr release. NT, not tested. 
[] See Table II. 
¶ See Table II. 
** P <  0.01 between the values obtained with lymphocytes with and without IF treatment. 
lower NK efficiency of the lymphocytes of the tumor patients  is reflected by the lower 
frequency  of allo-killing  (5%)  compared  with  the  14%  obtained  with  effectors  from 
healthy  donors.  There  was  no significant  difference between  the proportion  of IAK- 
positive tests of the patients  and  controls with allogeneic biopsy targets  (49 and  52%, 
respectively). 
Eight  osteosarcoma  patients  received IF therapy  at  the  time  of tumor  and  blood 
sampling.  The  results  with  this  group  of patients  did  not  differ  from  the  general 
pattern  either in the efficiency of the effectors or the sensitivity of the targets. 
Lymphocytes from  12 patients were assayed against  the K-562 and/or  Molt-4 lines. 
In all 26 tests  (Fig. 2) the IAK was elevated over the NK.  Repeated  tests gave similar 
results.  In accordance with previous findings, the NK  efficiency of lymphocytes from 
healthy  donors  was  stronger  than  that  of the tumor  patients.  The  mean  51Cr-release 
values in  healthy  donors  and  tumor  patients  was  44.8  and  14.5%  for K-562,  and  for 
Molt-4 63.4 and  27.6%,  respectively. 
Alteration  of the Cytotoxic  Susceptibility  of Biopsy  Cells after Cultivation.  In  three  experi- 
ments, the tumor cells were used as targets directly, after 5-6 d  of cultivation, or after 
preservation  in  frozen state.  The  effector cells were used  with  and  without  pretreat- 
ment  with IF (Table VI).  In accordance  with the above described  results,  IF did not 
affect  the  reactivity  against  fresh  or  frozen  stored  autologous  cells.  Lymphocytes  of 
three  healthy  individuals  and  of one  tumor  patient  (1 131)  showed  no  NK  against 
fresh  or  frozen  stored  allogeneic  targets,  whereas  IAK  was  efficient  in  two  of four F.  T.  VANKY, S.  A.  ARGOV,  S.  A.  EINHORN,  AND  E.  KLEIN  1159 
tests. After 6 d  in culture, the cytotoxic sensitivity of the biopsy cells increased, and, 
in  two  of three  tests,  the  ALC  was  positive  (2259  and  0788).  All  three  tests  were 
positive after IF treatment of the lymphocytes. 
In two of four cases, the cultured  targets were NK sensitive, and  in all four tests 
IAK sensitive. 
Discussion 
The lack of induction of ALC by in vitro IF treatment of the lymphocytes does not 
exclude the fact that in the complexity of the prevailing events, in vivo administration 
of IF can enhance the antitumor activity of the immune system. The immune response 
comprises interactions  between  several components,  humoral  and  cellular,  and  the 
outcome might be influenced  by IF acting on other levels than  the direct cytotoxic 
effect of lymphocytes. 
In previous experiments, ALC, i.e., cytotoxicity of the patients lymphocytes against 
their own  tumor cells,  was obtained  in  27%  of 198  cases.  The effects were usually 
weak. The reactivity was exerted by the T  cell-enriched subset and mainly autologous 
tumor cells were affected (29,  18). Although not proven, we may consider the in vitro 
cytotoxicity  as  a  manifestation  of  antitumor  autoimmunity.  Induction  of  DNA 
synthesis  in  lymphocytes by the  autologous  tumor  biopsy cells  (autologous  tumor 
stimulation  [ATS])  is  an  additional  parameter  that  suggests  the  occurrance  of a 
tumor-specific cellular reaction (30,  31). ATS was demonstrated in higher proportion 
of cases  (68%)  than  ALC  (32).  The  reason  why  ALC  was  not  influenced  by  IF 
treatment  of the  lymphocytes is  unclear.  It  may be a  result  of the  low number of 
antigen-recognizing lymphocytes and/or the weak expression of the relevant antigens 
on the targets. 
In studies concerned with the characteristics of the NK, freshly harvested targets 
were usually resistent or were weakly sensitive in short-term cytotoxicity tests (16).  In 
accordance, human tumor biopsy cells were rarely killed by allogeneic lymphocytes 
(18, 19). As shown in our results, when killing occurred, the effectors were exceptionally 
active against the standard NK targets. 
In one study, designed to clarify the conditions that influence the NK susceptibility 
of the target, it was shown that the sensitivity of the same mouse tumor line changed 
depending  upon  whether  it  was  derived  from cultures  or  from  animals  (17).  Our 
results with the human biopsy cells show a similar phenomenon. The reactivities that 
appear  after  in  vitro  cultivation  may  be  the  consequence  to  a  quantitative  or 
qualitative change in the expression of surface antigens.  Such changes after explan- 
tation  have in  fact been demonstrated  in  a  murine  lymphoma system both  for the 
histocompatibility (decrease)  and virus-determined antigens  (increase)  (33).  The TL 
antigen  expressed on certain  murine leukemias was also found  to be modulated,  it 
was  detectable  on  cells  kept  in  vitro  although  absent  from  cells  harvested  from 
immunized animals (34). Another alternative may be that in the conditions prevailing 
in culture those cell membrane properties that determine the sensitivity for cytotox- 
icity are changed. An increase in the sensitivity toward complement-mediated immune 
killing  was  observed  after  treatment  of the  targets  with  antimetabolites,  perhaps 
because of an effect on cell membrane repair mechanisms (35). 
We may also consider  the  possibility that  IF is  responsible for the  relatively low 
sensitivity of primary cells (10).  Immune IF may be produced  in the patients in the 1160  CELL-MEDIATED  KILLING OF  TUMOR  BIOPSY  CELLS 
course of an anti-tumor response, and this may cause the relatively low NK sensitivity 
of the tumor cells. These alternatives are speculative, and it remains to be seen what 
the  factor is  that  is  responsible  for the  changed susceptibility  toward  lymphocyte- 
mediated killing after explantation. 
The experiments revealed an interesting aspect concerning the involvement of the 
histocompatibility  antigens  in  the  natural  killing.  In  the  majority of NK  studies, 
cultured lines and most often tumor lines were used as targets. The recognition seems 
not  to  be  specific  because  sensitive  cells  are  killed  without  discrimination.  Tests 
performed with lymphocytes, of various individuals often differ in efficiency, but the 
ranking order of damage exerted on the various targets is similar (36, 37). 
NK phenomenon is operationally defined as the cytotoxicity exerted by lymphocytes 
harvested from individuals without known sensitization history toward the target. IF 
treatment is known to enhance this effect, and the effector cells of NK and IAK were 
shown to be in the same subsets (20).z IAK performed with the lymphocytes of donors 
without  known  immunization  toward  the  target  may be  regarded  as  an  enhanced 
NK phenomenon and also affects such targets that have low NK sensitivity. We may 
consider  the  situation  as  follows:  The  individual  lymphocytes in  the  population 
function at  various levels  of intensity.  For the different targets,  the threshold of the 
intensity necessary to bring about damage seems to differ, hence the differences in the 
proportion of target killed by a given number of effector cells.  It is unknown whether 
the critical factor acts at the event of establishment of the contact or at the event of 
the  lethal  hit.  The  results  of cold  target  inhibition  experiments  would suggest  the 
former because  the  competitive capacity of a  particular  target  usually  parallels  its 
cytotoxic sensitivity.  Two  sets  of experiments  provided evidence  that  the  elevated 
IAK, as compared with NK, in a  given system is a  result of recruitment of new cells 
that can kill  the target, rather than action on the already active cells  in such a  way 
that each kill an increased number of targets. These experiments were (a) comparative 
limiting dilutions of effectors in NK and IAK using the same target, which showed an 
increased  number  of active  samples  in  IAK;  2 and  (b)  elimination  of NK  cells  by 
preexposure of the  lymphocytes to  fibroblast  monolayer that  left  potentially active 
cells  inducible by IF treatment  (38).  In addition, results with an in vivo system also 
pointed to this mechanism. When rats were depleted of NK activity by radiation or 
drug treatment and injected with IF inducers, NK cells were found to reappear within 
a short time (39). 
A likely explanation for the allogeneic killing induced by IF in our experiments is 
a  polyclonal  activation  of the  cytotoxic potential  that  is  then  manifested  by  the 
lymphocytes committed  to  the  alloantigen  specificities  expressed  on  the  particular 
target  cells.  The role of the  specific receptors  may be  the  establishment  of contact 
between the interacting cells. Experiments concerned with the nature of NK and IAK 
have not yet revealed the recognition of alloantigens, although it may be the cause of 
a certain degree of  specificity and is often detectable superimposed on cross-reactivities. 
Some indications for the recognition of alloantigens were seen when in vivo activated 
murine killer cells were tested on macrophage targets in a  16-h assay. The effect was 
weaker on syngeneic compared with allogeneic targets  (40).  However, in other series 
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of experiments efficient killing of syngeneic primary target of nontumor origin such 
as thymus cells was reported (41). These latter effects may, however, also represent a 
killing as a result of the recognition of cell surface antigens. Mice are known to harbor 
endogenous viruses that impose surface antigens on certain cell types, and these are 
known to be recognized by the immune system (42).  It seems that the conditions  to 
reveal the alloantigen-determined killing have to be strict in the sense that cultured 
target cells have to be avoided. 
The activation of cytotoxic precursors by IF and the manifestation of cytotoxicity 
toward cells that carry alien histocompatibility antigens is similar to the findings with 
mitogen-activated  murine  cells.  The  murine  system  has  the  advantage  that  the 
influence of the major histocompatibility antigens can be easily studied in detail with 
co-isogeneic  strains.  The  phenomenon  described  by  several  authors  (43-45)  is  as 
follows: Spleen cells were activated in vitro with Concanavalin A  (Con A), and this 
killing effect was tested after the lectin was removed by incubation with a-methyl-D- 
mannoside.  Cytotoxicity  was  exerted  by  the  activated  lymphocytes  only  toward 
targets  that  expressed  alien  major histocompatibility complex  (MHC)  locus-deter- 
mined  antigens.  Differences  in  the  loci  of minor  histocompatibility  antigens  and 
expression of tumor-related antigens were not sufficient to bring about this reaction. 
This type of cytotoxicity differed from that obtained in the presence of lectin, which 
was  indiscriminative  and  also  affected  histocompatibile  cells.  The  interpretation 
proposed was that  Con  A  activates precursors  for expression of cytotoxic potential 
and in a  particular test the clone that was committed to the MHC antigens present 
on the target exerted the killing. Because it is known that the frequency oflymphocytes 
that recognize MHC antigens is high, such cytotoxicities are often measurable without 
the necessity of the enlargement of the reactive clone. This mechanism may also be 
applicable to the NK and IAK systems due to the restriction to allogeneic targets. 
The  search  for  a  particular  antigen  responsible  for  the  NK effect  did  not  give 
support  for  the  existence  of  a  well-defined  entity.  It  is  possible  that  membrane 
properties  of cultured  cell  lines  contribute  to  the  interaction  with  the  killer  cells. 
Similar to the cytotoxicity in the presence of lectins, such interactions have a certain 
specificity inasmuch as targets from the same species are affected with considerably 
higher efficiency than xenogeneic targets that are sensitive to the NK exerted by the 
lymphocytes of their own species (36, 46). It is known that the number of lymphocytes 
that  recognize  cell  surface  antigens  of an  alien  species  is  relatively low.  A  species- 
specific recognition on the cell membrane level has also been indicated when T  cells 
and  thymocytes were  admixed  to  various  target  cells.  They attached  to  cells  in  a 
species-specific pattern, distinguishing their own and closely related species (47). 
The cell membrane property acquired in culture conditions that contribute to the 
suicidal  interaction  with  the  lymphocytes is  unknown.  With  freshly harvested  cells 
this factor is absent, and the effect exhibited by lymphocytes of the unprimed donors 
(NK)  may be the  consequence  of a  certain,  individually  variable,  degree of T  cell 
activation (the active cells have been shown to be within the T  subset)  (48, 49). Those 
activated T  cells that  recognize the antigens determined by MHC on the target can 
establish the contact and exert the killing function. IF or IF inducers recruit potential 
killer cells. All evidences point to the fact that the lymphocyte cytotoxicities without 
manipulation and after IF activation are similar in the ranking order of the efficiencies 
exhibited  by various subsets and  in  the sensitivities of various targets.  According to 1162  CELL-MEDIATED  KILLING OF TUMOR  BIOPSY CELLS 
this view, the NK (and IAK) effect would be related to cytotoxic T  lymphocytes when 
assayed on fresh  targets,  whereas  with  some cultured  cell  lines  tested  in short-term 
assays,  as  a  result  of yet  undefined  properties  of their  plasma  membrane,  events 
similar to the cytotoxicity in the presence of lectins could occur. 
Summary 
Blood  lymphocytes  of patients  with  solid  tumors  were  assayed  for  cytotoxicity 
against  autologous  and  allogeneic  primary  tumor  cells.  The  lymphocytes  killed 
autologous tumor cells in 7 of 25 cases (28%) and allogeneic tumor cells in 2 of 37 tests 
(5%).  Lymphocytes from healthy  donors were  rarely  cytotoxic for the  biopsy cells, 
which indicates that these cells have low natural  killer sensitivity. 
The autoreactivity that  may reflect  the immunological recognition of tumor cells 
was  not  altered  by  pretreatment  of the  effectors  with  interferon  (IF).  In  contrast, 
killing of allogeneic tumor biopsy cells was induced by IF in ~50% of tests, with the 
lymphocytes of both the tumor patients  and the healthy donors. The mechanism of 
the alloreactivity is most likely a  consequence of IF-induced polyclonal activation of 
cytotoxic potential  and the lymphocytes that are committed to recognize the alloan- 
tigens expressed on the particular target manifest the killing function. 
When  the  biopsy  cells  were  explanted  and  kept  in  culture  for  5-6  d,  their 
susceptibility  for the lymphocyte damage increased,  and they were killed  by the IF- 
treated ceils also in autologous combinations.  Whether this change in sensitivity  is a 
result of qualitative or quantitative changes in antigen expression or of other changes 
in the properties of the cell membrane is unknown. 
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